Skip to main content
. 2018 Jan 9;168(3):655–666. doi: 10.1007/s10549-017-4639-0

Table 2.

Characteristics of all women and tumors with detected breast cancer

Patient ID Screening visit Age at BrC diagnose Menopaus status Risk group BOADICEA life time riskd Modalities that detected malignancyc Density according to Wolfe Type of surgery Size (mm) DCIS
Yes/no		 Invasive histology type
Characteristics of the 20 women and tumors with a screened detected breast cancer
 1001 6 56 Post History of BrC na MRI P2 BCS No Ductal
 1037 2 48 Post History of BrC na US, CBE P2 Extirpation of local recurrence No Ductal
 1064 2 61 Post History of BrC na US, CBE DY MAD No Ductal
 1109 5 49 Pre Moderate risk 20 XRM P2 BCS No Ductal
 1130 4 46 Post Moderate risk 15 MG US, CBE P1 MAD No Ductal
 1167 1 48 Pre Moderate risk 17 US DY MAD Yes Metaplastic
 1183 4 40 Pre BRCA1 76 US, MRI, CBE P2 MAD Yes Unclassified
low diff
 2009 4 44 Pre BRCA1 77 US (pregnant) N1b MAD No Ductal
 2028 1 60 Post High risk 46 US P1 MAD No Ductal
 2067 4 47 Pre High riska 19 US, CBE P1 MAD Yes Ductal
 2088 2 61 Post History of BrC na MG, US N1 BCS No Tubular
 2132 5 56 Post High risk 17 US P2 BCS No Ductal
 2151 5 54 Pre Moderate risk 16 US P1 BCS No Lobular
 2239 4 55 Post High riska 28 MG, US P2 MAD No Ductal
 3023 4 58 Pre BRCA1 60 US, CBE P1 MAD No Ductal
 3053 2 53 Post High risk 28 MG P2 MAD 30 na
 3070 6 55 Post High risk 29 MG P2 BCS 2 na
 3097 6 59 Post High risk 23 US, CBE P1 MAD No Ductal
 3113 6 57 Post High risk 21 US P1 BCS No Lobular
 3152 1 39 Pre Moderate risk 17 MG, US, CBE P2 MAD 43 Ductal
Patient ID Invasive tumor size (mm) Grade of invasive cancer ER/PR No. of positive lymph nodes Proliferation (%) HER2 TNM Chemotherapy Type of radiotherapy Identified mutation after BrC-diagnose Follow-upg
Characteristics of the 20 women and tumors with a screened detected breast cancer
 1001 8 2 pos/pos 0 25 neg T1bN0M0 No Breast Relapse free 10 years
 1037 16 2 pos/pos 0 10 neg T1cN0M0 No Tumor area Relapse free 3 years, then metastases and dead after 10 years
 1064 20 3 pos/neg 0 20 neg T1cN0M0 No None Relapse free 13 years
 1109 8 2 pos/pos 0 15 neg T1bN0M0 No Breast + boost Relapse free 4 years, then death due to other cause
 1130 15e na pos/pos 1 50 neg T2N1M0 No Breast + locoregional Relapse free 9 years
 1167 11 3 pos/pos 0 30 neg T1cN0M0 Yes None Relapse free 11 years
 1183 CRf 3 neg/neg 4 50 neg T1cN1M0 No Locoregional Relapse free 1 year, then metastases and death after 2 years
 2009 23 3 neg/neg 0 54 neg T2N0M0 Yes None Relapse free 12 years
 2028 9 2 pos/pos 0 < 2 neg T1bN0M0 No None Contralateral BrC after 12 years but no signs of relapse 15 years after first BrC diagnose
 2067 24 3 neg/neg 0 65 neg T2N0M0 Yes None BRCA1 Relapse free 11 years
 2088 10 1 pos/pos 0 3 neg T1bN0M0 No Breast Relapse free 13 years
 2132 9 2 pos/pos 0 10 neg T1bN0M0 No Breast Relapse free 9 years
 2151 20 2 pos/neg 0 2 neg T1cN0M0 No Breast Relapse free 9 years
 2239 17 3 pos/pos 1 23 neg T1cN1M0 Yes Locoregional BRCA1 Relapse free 9 years
 3023 9 3 neg/neg 0 60 neg T1bN0M0 No None Relapse free 10 years, then death due to pancreas cancer 11 years after BrC diagnose
 3053 no na na na na na DCIS No None Relapse free 13 years
 3070 no na na na na na DCIS No None Relapse free 8 years
 3097 20 2 pos/neg 1 20 neg T1cN1M0 Yes None Relapse free 8 years
 3113 10 2 pos/pos 0 18 neg T1bN0M0 No Breast Relapse free 7 years
 3152 22 3 pos/neg 2 23 neg T2N1M0 Yes None Relapse free 11 years
Patient ID Screening visit Age at BrC diagnose Menopaus status Risk group BOADICEA life time riskd How the tumors were detected Density previous year Type of surgery Size (mm) DCIS
Yes/no		 Invasive histology type
Characteristics of the 10 women and tumors detected in between screening rounds
 1051 na 46 na Moderate riska 19 MG—population screening P1 Mastectomy 12 na
 1178 na 41 na Moderate risk 16 MG—population screening na MAD No Ductal
 2020 na 37 Pre BRCA2 88 Detected at PM P2 PM 5 na
 2181 na 39 Pre Moderate risk 19 BSE P2 MAD No Ductal
 2208 na 60 Post Moderate risk 21 BSE P2 MAD No Lobular
 2043 na 50 Pre Moderate riska 16 BSE P2 MAD No Lobular
 2252 na 49 Pre Moderate risk 14 MR due to unspecific symptom P2 BCS 40 Ductal
 2269 na 30 Pre BRCA1 93 BSE P2 BCS 5 Ductal
 3015 na 48 Pre High riska 31 BSE P2 MAD No Ductal
 3073 na 52 Pre BRCA2 71 Minimal area with DCIS detected at PM P2 PM na na
Patient ID Invasive tumor size (mm) Grade of invasive cancer ER/PR No. of positive lymph nodes Proliferation (%) HER2 TNM Chemotherapy Type of radiotherapy Identified mutation after BrC-diagnose Follow-upg
Characteristics of the 10 women and tumors detected in between screening rounds
 1051 no na na na na na DCIS No none BRCA2 Relapse free 12 years
 1178 9 3 neg/neg 3 90 neg T1bN1M0 Yes none Relapse free 11 years
 2020 no na na na na na DCIS No none Relapse free 11 years
 2181 80 2 pos/pos 0 80 neg T3N0M0 Yes Locoregional Relapse free 12 years
 2208 11 2 pos/neg 0 2 neg T1cN0M0 No None Relapse free 10 years
 2043 15 2 pos/pos 1 21 neg T1cN1M0 Yes None BRCA2 Relapse free 14 years
 2252 15 2 pos/pos 4 0 neg T1cN1M0 Yes Locoregional Relapse free 8 years
 2269 5 3 neg/neg 0 75 neg T1aN0M0 Yes Breast + boost Relapse free 6 years
 3015 20 3 pos/pos 3 1 pos T1cN1M0 Yes Locoregional BRCA1 Relapse free 14 years
 3073 no na na na na na DCIS No None Relapse free 12 years, then local recurrence in left breast 12 mm ductal carcinoma

MG mammography, CBE clinical breast examination, BSE breast self-examination, BrC breast cancer, MRI magnetic resonance imaging, MAD mastectomy and axillary dissection, PM prophylactic mastectomy, BCS breast-conserving surgery, pos positive, neg negative, TNM tumor, node and metastasis staging for breast cancer

aMutation was found after BrC

bDensity previous screening round

cMRI was only performed in two patients; 1001, 1183

dBoadicea was calculated retrospectively

e35 mm before neoadjuvant chemotherapy

f17 mm before neoadjuvant chemotherapy, na; non-applicable

gInformation from medical records October 2017